STAT
FEBRUARY 12, 2024
We accept all manner of confidential communications and secret dossiers … New diabetes and weight loss drugs may benefit patients undergoing hip replacement without adding to complication risks , Reuters reports, citing preliminary data released at a meeting of orthopedic surgeons. Meanwhile, here are a few tidbits to digest.
European Pharmaceutical Review
NOVEMBER 2, 2022
The report suggested health research is a key area for R&D investment to align activity with broader social goals, communicate a clear strategic direction and improve R&D funding by crowding novel investment. . percent of GDP by 2030, to level with R&D investment in Sweden, the US and Taiwan. billion over a decade.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JANUARY 27, 2023
.” “Efforts to expand access to medicines, especially insulin, are only beneficial when effective cold chain systems are in place to keep them at the right temperature on their way to patients,” commented Leigh Ann Pusey, Executive Vice President of corporate affairs and communications for Lilly.
European Pharmaceutical Review
DECEMBER 15, 2022
Lilly’s 30×30 initiative aims to improve access to quality healthcare for 30 million people living in limited-resource settings, annually, by 2030. Communication with WHO encourage implementation of and accountability for the commitments and contributions toward improving access to insulin.
Pharmafile
JANUARY 6, 2023
It is hoped this acceleration will lead to up to 10,000 patients receiving such therapies by the end of 2030. German biotech company BioNTech and the UK Government have signed a Memorandum of Understanding (MoU) which will accelerate clinical trials of personalised mRNA immunotherapies. read more.
PharmD Live
MAY 13, 2024
Their projections indicate that approximately 10,000 people will turn 65 each day over the next 19 years, with the population of older adults expected to double to 80 million by 2030. At this rate, nearly half of the older population could be impacted by polypharmacy by 2030. Data from the U.S. in 1994 to 42.4%
pharmaphorum
AUGUST 20, 2020
According to a 2018 landmark report by the Lancet Commission, the growing mental health epidemic could cost the international economy up to $16 trillion by 2030 , with a dramatic impact on productivity and quality of life. Economically speaking, Americans lose approximately $193.2
Expert insights. Personalized for you.
116 
Let's personalize your content